Samsung Biologics (KRX:207940) signed a biologics contract manufacturing deal with an undisclosed EU-based pharmaceutical company, the South Korean firm said in a Tuesday corporate filing with KIND.
The contract, valid till December 2030, is valued at 2.074 trillion won.
Shares of the South Korean firm rose more than 1% in recent trade on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.